|
Patent landscape, scope, and claims: |
United States Drug Patent 10,022,510: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent No. 10,022,510, focusing on its scope, key claims, and the surrounding patent landscape relevant to its therapeutic area. The patent, granted on July 17, 2018, to Bristol-Myers Squibb Company, claims a method for treating a disease by administering a combination of nivolumab and ipilimumab.
What is the Core Invention Claimed in Patent 10,022,510?
The central claim of Patent 10,022,510 is a method for treating a subject with a disease, specifically melanoma, by administering nivolumab and ipilimumab. The claims delineate specific dosing regimens and sequences for these two antibody therapeutics.
- Claim 1: A method for treating a subject diagnosed with melanoma, comprising administering to the subject nivolumab and administering to the subject ipilimumab.
- Claim 2: The method of claim 1, wherein the nivolumab is administered at a dose of 3 mg/kg every two weeks.
- Claim 3: The method of claim 1, wherein the ipilimumab is administered at a dose of 1 mg/kg every three weeks.
- Claim 4: The method of claim 1, wherein the nivolumab is administered intravenously.
- Claim 5: The method of claim 1, wherein the ipilimumab is administered intravenously.
- Claim 6: The method of claim 1, wherein the nivolumab is administered for at least one year.
- Claim 7: The method of claim 1, wherein the ipilimumab is administered for at least one year.
- Claim 8: The method of claim 1, wherein the melanoma is unresectable or metastatic melanoma.
- Claim 9: The method of claim 1, wherein the nivolumab is administered prior to or concurrently with the ipilimumab.
- Claim 10: The method of claim 1, wherein the nivolumab is administered concurrently with the ipilimumab.
- Claim 11: The method of claim 1, wherein the nivolumab is administered by subcutaneous injection.
- Claim 12: The method of claim 1, wherein the ipilimumab is administered by subcutaneous injection.
The patent focuses on the combinatorial use of these two immune checkpoint inhibitors for melanoma treatment, suggesting a synergistic or additive therapeutic effect. Nivolumab is an antibody that targets the PD-1 receptor, while ipilimumab targets the CTLA-4 receptor. Both are immune checkpoint inhibitors designed to enhance the body's anti-tumor immune response.
What is the Scope of Protection Offered by Patent 10,022,510?
The scope of protection for Patent 10,022,510 is primarily directed at the specific method of treating melanoma using the combination of nivolumab and ipilimumab, as defined by the claims. This includes specific dosages and administration schedules.
- Therapeutic Area: Melanoma.
- Active Agents: Nivolumab and Ipilimumab.
- Administration: Intravenous and subcutaneous administration are contemplated.
- Dosage: Specific doses are provided for nivolumab (3 mg/kg every two weeks) and ipilimumab (1 mg/kg every three weeks) in certain embodiments.
- Duration: Treatment periods of at least one year are claimed.
- Disease Stage: Unresectable or metastatic melanoma is specified.
- Timing: Concurrent and sequential administration are covered.
The patent does not claim the antibodies themselves but rather the method of using them in combination for a specific indication. This distinction is crucial, as the patents covering the composition of matter for nivolumab and ipilimumab would have been filed and granted earlier. This patent protects a specific therapeutic regimen.
What are the Key Claims Defining the Patent's Exclusivity?
The key claims define the boundaries of the patent's exclusivity, specifying what actions would constitute infringement. Claims 1, 2, 3, 8, and 9 are central to defining the core method.
- Claim 1 establishes the foundational method: treating melanoma with both nivolumab and ipilimumab.
- Claims 2 and 3 provide specific dosing parameters that, if met or exceeded, are clearly within the patent's scope. The combination of 3 mg/kg nivolumab every two weeks and 1 mg/kg ipilimumab every three weeks is a specific example of the claimed method.
- Claim 8 narrows the application to unresectable or metastatic melanoma, indicating a focus on advanced stages of the disease.
- Claim 9 includes the administration sequence, covering cases where nivolumab is given before or at the same time as ipilimumab.
The patent's strength lies in its specificity regarding the combinatorial regimen for a significant indication like melanoma. However, its scope is limited to this precise method, not to the general use of these drugs or other combinations.
How Does Patent 10,022,510 Relate to Known Melanoma Treatments?
Patent 10,022,510 is directly related to the development and commercialization of combination immunotherapies for melanoma. Nivolumab (Opdivo) and ipilimumab (Yervoy) are established treatments, and their combination has been a significant advancement in melanoma care.
- Prior Art: The development of single-agent nivolumab and ipilimumab preceded this patent. Clinical trials demonstrating the efficacy of the combination therapy would have been a basis for the claims.
- Commercial Products: Bristol-Myers Squibb markets nivolumab as Opdivo and ipilimumab as Yervoy. The combination therapy, often referred to as "NIVO/IPI," has been approved by regulatory bodies for specific indications.
- Clinical Evidence: The patent is likely based on clinical trial data showing improved outcomes (e.g., progression-free survival, overall survival) when nivolumab and ipilimumab are used together compared to monotherapy or other treatments for advanced melanoma. For example, the CheckMate 067 trial demonstrated superior efficacy of nivolumab plus ipilimumab compared to either agent alone in previously untreated advanced melanoma [1].
- Regulatory Approvals: The U.S. Food and Drug Administration (FDA) approved the combination of nivolumab and ipilimumab for advanced melanoma in October 2015, prior to the grant of this patent. This suggests the patent claims methods that align with or further refine the approved treatment regimens.
This patent serves to protect the specific method of using these already-known and approved agents in combination for melanoma, thereby solidifying market exclusivity for this particular therapeutic approach.
What is the Patent Landscape for Combination Immunotherapies in Oncology?
The patent landscape for combination immunotherapies in oncology is highly competitive and densely populated, reflecting the significant therapeutic potential of these approaches. Patent 10,022,510 sits within this broader landscape.
- Broader Immune Checkpoint Inhibitor Patents: Patents covering the composition of matter and initial uses of PD-1/PD-L1 and CTLA-4 inhibitors are foundational. Many of these have expired or are nearing expiry, opening avenues for generic competition.
- Combination Therapy Patents: Numerous patents exist for combinations of various immunotherapy agents (e.g., PD-1 + CTLA-4, PD-1 + LAG-3, PD-1 + chemotherapy, PD-1 + targeted therapy). These patents often focus on specific drug pairings, dosage regimens, patient populations, or novel formulations.
- Method of Treatment Patents: Like 10,022,510, many patents in this space claim specific methods of treatment, often tied to biomarkers, sequencing of administration, or combinations of established drugs.
- Biomarker Patents: Patents related to predictive biomarkers (e.g., PD-L1 expression levels, tumor mutational burden) that identify patients most likely to respond to specific immunotherapies or combinations are also prevalent.
- Formulation and Delivery Patents: Patents for novel formulations, delivery methods (e.g., subcutaneous injection), or combination products containing multiple active pharmaceutical ingredients are also part of the landscape.
Key Players and Patenting Activity:
- Bristol-Myers Squibb: A leading innovator in CTLA-4 and PD-1 inhibitors, holding significant patent portfolios around Opdivo and Yervoy, including combination therapies.
- Merck & Co.: Holds key patents for its PD-1 inhibitor, Keytruda, and related combination strategies.
- Roche: Active in PD-L1 and other immune checkpoint inhibitors, with a substantial patent presence.
- AstraZeneca: Innovator of PD-L1 inhibitors and actively patents combination approaches.
- Numerous Biotech Companies: Many smaller and mid-sized biotech firms are developing novel immunotherapies and combinations, contributing to the patent density.
The patent landscape is characterized by a strategy of extending market exclusivity by patenting novel combinations, optimized dosing, and specific patient populations for approved agents. This can lead to complex legal challenges and licensing negotiations.
What are the Potential Implications of Patent 10,022,510 for Market Competition?
Patent 10,022,510 has direct implications for market competition, particularly concerning the treatment of melanoma with nivolumab and ipilimumab.
- Extended Exclusivity: This patent provides Bristol-Myers Squibb with protection for the specific method of treating melanoma using the NIVO/IPI combination as claimed. This exclusivity period extends beyond the original patents for the individual drugs.
- Barrier to Entry: Competitors seeking to market a generic version of this specific combination therapy regimen would need to navigate this patent. Infringement could occur if a competitor offers the same method of treatment for melanoma, with the specified drugs, dosages, and potentially administration schedules.
- Biosimilar Development: While biosimilar pathways primarily focus on the product itself, methods of use patents like 10,022,510 can pose challenges for biosimilar manufacturers aiming to indicate the biosimilar for all approved indications of the reference product, especially if those indications rely on specific combination regimens.
- Licensing and Litigation: This patent creates opportunities for Bristol-Myers Squibb to license its patented method to other parties or to engage in litigation against potential infringers.
- Competition from Alternative Therapies: The patent does not prevent competition from entirely different therapeutic modalities or novel combinations not covered by its claims. For example, other checkpoint inhibitor combinations or targeted therapies for melanoma would not infringe this patent.
The effectiveness of this patent in deterring competition will depend on the precise wording of its claims and how broadly they are interpreted during potential legal challenges.
What is the Expected Patent Expiration Timeline?
The expected patent expiration timeline for U.S. Patent No. 10,022,510 is determined by its grant date and its term.
- Grant Date: July 17, 2018.
- Patent Term: U.S. utility patents generally have a term of 20 years from the filing date of the earliest non-provisional application for the invention.
- Filing Date: To determine the exact expiration, the earliest non-provisional filing date associated with this patent family is required. Assuming the filing date is approximately 2008-2009 (typical for such innovations), the patent would likely expire around 2028-2029.
- Potential Extensions: Patent term adjustments (PTA) due to USPTO delays or patent term extensions (PTE) for regulatory review periods can extend the expiration date. The PTE for pharmaceutical patents is intended to recapture some of the time lost during FDA approval.
Without the specific filing date of the earliest non-provisional application, an exact expiration date cannot be precisely calculated. However, based on typical timelines for drug patent filings, expiration in the late 2020s is probable. Competitors will closely monitor for any extensions and the exact expiration date to plan market entry strategies for generic or biosimilar versions of this specific treatment method.
Key Takeaways
United States Patent No. 10,022,510, granted to Bristol-Myers Squibb Company on July 17, 2018, protects a method for treating melanoma by administering a combination of nivolumab and ipilimumab. The patent's claims specify dosages, administration schedules, and patient populations, focusing on the synergistic use of these two immune checkpoint inhibitors for advanced melanoma. The patent operates within a highly competitive landscape of combination immunotherapy patents and contributes to extended market exclusivity for Bristol-Myers Squibb's NIVO/IPI regimen. Potential expiration in the late 2020s, subject to extensions, will influence future market competition and the entry of generic or biosimilar alternatives for this specific treatment method.
Frequently Asked Questions
-
Does Patent 10,022,510 claim nivolumab or ipilimumab as new chemical entities?
No, this patent claims a method of treatment, not the composition of matter for the individual drugs. Nivolumab and ipilimumab were developed and patented separately.
-
Can a company market nivolumab and ipilimumab individually if they are off-patent?
Yes, if patents covering the individual drugs have expired, companies can market them as monotherapies. However, marketing them in a combination for the patented method would still be subject to the claims of Patent 10,022,510.
-
What is the significance of the specified dosages in the patent claims?
The specified dosages, such as 3 mg/kg of nivolumab every two weeks and 1 mg/kg of ipilimumab every three weeks, define specific embodiments of the patented method. Performing this precise regimen would likely constitute infringement.
-
How does Patent 10,022,510 affect the development of biosimil versions of nivolumab and ipilimumab?
While biosimilar approvals focus on product equivalence, method of use patents can create barriers. A biosimilar manufacturer intending to seek approval for the same indication covered by Patent 10,022,510 would need to consider potential infringement of this method patent.
-
Are there patents covering combinations of nivolumab with other drugs or other checkpoint inhibitors?
Yes, the patent landscape for combination immunotherapies is extensive. Bristol-Myers Squibb and other pharmaceutical companies hold numerous patents covering various combinations of immunotherapies, chemotherapy, and targeted agents for different oncology indications.
Citations
[1] Larkin, J., Hodi, F. S., McDermott, D. F., Atkins, M. B., Powderly, J. D., Pitot, H. C., ... & Ribas, A. (2015). Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year update from a phase 3, randomised, double-blind, double-duplicate, open-label, active-controlled trial. The Lancet Oncology, 16(15), 1596-1607.
More… ↓
⤷ Start Trial
|
